Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CYP4A11/CYP4F2-IN-2 是一种有效的和具有口服活性的细胞色素 P450 (CYP) 4A11 和 CYP4F2 的双重抑制剂,IC50 值分别为 140 nM 和 40 nM。CYP4A11/CYP4F2-IN-2可从肝脏和肾脏中提取, 具有治疗肾脏疾病的潜力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 445 | 现货 | ||
5 mg | ¥ 995 | 现货 | ||
10 mg | ¥ 1,730 | 现货 | ||
25 mg | ¥ 3,390 | 现货 | ||
50 mg | ¥ 4,990 | 现货 | ||
100 mg | ¥ 6,960 | 现货 | ||
500 mg | ¥ 14,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,180 | 现货 |
产品描述 | CYP4A11/CYP4F2-IN-2 is a potent and orally active dual inhibitor of cytochrome P450 (CYP) 4A11 and CYP4F2, with IC50 values of 140 nM and 40 nM, respectively. CYP4A11/CYP4F2-IN-2 can be extracted from liver and kidney and has the potential to treat kidney diseases. |
靶点活性 | CYP4A11:140 nM, 20-HETE:29 nM, CYP4F2:40 nM |
体外活性 | CYP4A11/CYP4F2-IN-2 suppresses 20-Hydroxyeicosatetraenoic acid (20-HETE) production from arachidonic acid in human renal microsomes, with an IC50 of 29 nM.[1] |
体内活性 |
CYP4A11/CYP4F2-IN-2 (0.03-1 mg/kg; a single p.o.) effectively inhibits renal 20-HETE production in rats in a dose-dependent manner.[1]
CYP4A11/CYP4F2-IN-2 (0.5 mg/kg; i.v.) demonstrates a low clearance rate (1430 mL/h/kg), a moderate volume of distribution (763 mL/kg), and short half-life (0.424 h) in mice.[1] CYP4A11/CYP4F2-IN-2 (1 mg/kg; i.v.) exhibits low clearance (226 mL/h/kg), moderate volume of distribution (839 mL/kg), and a half-life of (3.01 h) in SD rats.[1] CYP4A11/CYP4F2-IN-2 (1 mg/kg; p.o.) shows a maximum concentration (623 ng/mL), a half-life of (3.03 h), and high bioavailability (97.7%) in SD rats.[1] |
分子量 | 300.36 |
分子式 | C16H20N4O2 |
CAS No. | 2126874-77-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22.5 mg/mL (74.9 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.3293 mL | 16.6467 mL | 33.2934 mL | 83.2335 mL |
5 mM | 0.6659 mL | 3.3293 mL | 6.6587 mL | 16.6467 mL | |
10 mM | 0.3329 mL | 1.6647 mL | 3.3293 mL | 8.3233 mL | |
20 mM | 0.1665 mL | 0.8323 mL | 1.6647 mL | 4.1617 mL | |
50 mM | 0.0666 mL | 0.3329 mL | 0.6659 mL | 1.6647 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CYP4A11/CYP4F2-IN-2 2126874-77-7 Metabolism P450 CYP4A11/CYP4F2IN2 Inhibitor inhibitor inhibit